Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase II Study of the EORTC Brain Tumor Group (EORTC Protocol 1410-BTG) Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas

Trial Profile

Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase II Study of the EORTC Brain Tumor Group (EORTC Protocol 1410-BTG) Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Depatuxizumab mafodotin (Primary) ; Lomustine; Temozolomide
  • Indications Glioblastoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms INTELLANCE 2
  • Sponsors AbbVie
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 21 Feb 2017 Planned End Date changed from 1 Dec 2019 to 1 Jun 2020.
    • 01 Nov 2016 Planned number of patients changed from 240 to 260.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top